Extrapyramidal Symptoms and Tolerability of Olanzapine Versus Haloperidol in the Acute Treatment of Schizophrenia

摘要: Background: A relative lack of extrapyramidal symptoms (EPS, i.e., the syndromes dystonia, parkinsonism, akathisia, dyskinesia) is one criterion used to determine whether an antipsychotic atypical. The symptom profiles novel olanzapine and conventional haloperidol were compared in a population 2606 patients from three well-controlled prospective clinical trials. Method: Extrapyramidal data analyzed for 1796 treated with (5 20 mg/day) 810 up 6 weeks therapy. Patients monitored weekly by methods assessment : (1) detection adverse events (signs symptoms) casual observation, nonprobing inquiry, spontaneous report; (2) objective rating scale scores; (3) use concomitant anticholinergic medications. Emergence EPS was assessed analysis incidence syndrome categories based on events, categorical scores, mean maximum change (4) medication use. Outcome scores at endpoint endpoint. Results: Olanzapine statistically significantly (p = .014, p <.001) superior all four analyses related emergence two outcome. Furthermore, during acute treatment, fewer (0.3%) discontinued study because any event than (2.7%, <.001). Conclusion: exhibited lower profile comparably effective doses. evident despite more frequent drugs among haloperidol-treated patients. Fewer olanzapine-treated EPS, suggesting that should contribute better compliance longer term maintenance minimal anticholinergic-associated events.